Skip to main content

Swayam Pakula Ramakant (R.K.)

Analyst

H.C. Wainwright

Equibles does not estimate personal net worth.

About Swayam Pakula Ramakant (R.K.)

Swayam Pakula Ramakant (R.K.) is recorded as Analyst at H.C. Wainwright. Swayam Pakula Ramakant (R.K.) has spoken on 5 earnings calls across 5 companies, most recently for Intensity Therapeutics, Inc. on August 11, 2026. Those appearances were for Intensity Therapeutics, Inc. (INTS), INNATE PHARMA, Absci Corp (ABSI), Eton Pharmaceuticals, Inc. (ETON) and Vericel Corp (VCEL). The companies whose calls Swayam Pakula Ramakant (R.K.) spoke on are classified in the Healthcare sector.

Swayam Pakula Ramakant (R.K.) on recent calls

“And then, Lou, will all the 21 patients that had been enrolled before the pause remain in the primary intent-to-treat analysis? And, you know, did the interruption affect anything, especially the anticipated timing or number of overall survival events that need to happen?”
Analyst — H.C. Wainwright, Second Quarter 2026 Financial Results Conference Call ·
“You know, regarding the Nectin 4 ADC, you know, you're – it's just Lily's products, which are in phase one, and bicycles, you know, recently deprioritized their product.”
Analyst — H.C. Wainwright, INNATE PHARMA Q1 FY2026 Earnings Call ·
“I apologize that I'm going to disappoint you by not asking your question on 201 or 202. However, I have a couple of other questions. One is you stated that you're de-emphasizing oncology products.”
Analyst — H.C. Wainwright, Absci Corp Q1 FY2026 Earnings Call ·
“Just to talk a little bit about the Kindevia launch. You know, you were stating that there are about 60% of the patients are age 4 and older. That's four and below, I'm sorry, that's four and below, sorry, four and below, yeah, I'm reading wrong from my notes.”
Analyst — H.C. Wainwright, Eton Pharmaceuticals, Inc. Q2 FY2025 Earnings Call ·
“So in your prepared remarks, Joe, you were talking about there's a potential for the burn franchise to outperform your 10 million per quarter guidance. So what are the pushes and pulls for that to happen?”
Analyst — H.C. Wainwright, Vericel Corp Q2 FY2025 Earnings Call ·

Affiliation history

  • H.C. Wainwright

    Analyst

    Transcript header (unverified)

    Current

Company network

INNATE PHARMA

Biotechnology · Healthcare

1 appearance Latest appearance 2026-05-13

Recent activity